A Phase 3 interventional study of BAY 59-7939 and BAY 59-7939 in Pulmonary Embolism, Thromboembolism and Thrombosis, sponsored by Bayer. Completed at 267 sites in 31 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-19.
Sponsored by Bayer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing rivaroxaban in Pulmonary Embolism — 4 open to participants now, 6 under way, 2 of them phase 3. Rivaroxaban · Pulmonary Embolism.
Among the 20 studies testing rivaroxaban in Pulmonary Embolism, this one is the 5th largest by enrollment, is the only one that started in 2014, is one of 7 in phase 3, and was the 6th registered.
832 studies on the registry are indexed under Pulmonary Embolism; 171 are open to participants now.
Browse Pulmonary Embolism studies →4 of the 20 studies testing rivaroxaban in Pulmonary Embolism are open now, in 8 countries. Recruiting first, the newest first:
Prof. Stavros Konstantinides, MD · Sites in Austria, Germany
Ages 18–85
Medical University of Gdansk · Sites in Poland
Ages 18+
University Hospital, Angers · Sites in France
Ages 18+
Drahomir Aujesky · Sites in Belgium, Canada, France and 2 more countries
Ages 18+
By country, each count listing its studies:
Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 129 Pulmonary Embolism studies recruiting now, 109 (84%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 8 · Phase 4 6
First in 2004; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,365 is above the median of 174 across 429 interventional studies indexed under Pulmonary Embolism.
Median enrollment 241 across the 20 interventional studies. Of the 14 that completed or were terminated, 7 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 20 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
15 studies in Pulmonary Embolism by Bayer: none open now, none under way, none of them phase 3. Of 14 finished, 4 (29%) have results posted.
Among the 15 studies in Pulmonary Embolism by Bayer, this one is one of 2 that started in 2014, is one of 4 in phase 3, and was the 10th registered.
Bayer’s Pulmonary Embolism studies by the year they started, since 2004.
2 of the studies testing rivaroxaban in Pulmonary Embolism that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06611319Phase 3Prof. Stavros Konstantinides, MDENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty | 2027-03 |
| NCT03129555Herlev and Gentofte HospitalThe Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE) | 2027-03-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies testing rivaroxaban in Pulmonary Embolism, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bayer’s 15 in Pulmonary Embolism:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, double-blind, event-driven, superiority study for efficacy.
Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism) who completed 6 or 12 months of treatment of anticoagulation are eligible for this trial
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rivaroxaban 10 mg once daily for 12 months
Drug: BAY 59-7939
Rivaroxaban 20 mg once daily for 12 months
Drug: BAY 59-7939
ASA (Acetylsalicylic Acid) 100 mg once daily for 12 months
Drug: ASA
10 mg tablet once daily for 12 months
20 mg tablet once daily for 12 months
100 mg tablet once daily for 12 months
Number of Participants With the Composite of Fatal or Non-fatal Symptomatic Recurrent Venous Thromboembolism
The primary efficacy outcomes (i.e., recurrent venous thromboembolism \[VTE\] defined as composite of fatal or non-fatal symptomatic recurrent VTE, including unexplained death for which pulmonary embolism \[PE\] could not be ruled out) as confirmed by the central independent adjudication committee (CIAC) were considered up to the end of the individual intended duration of treatment. Incidence of the composite of the primary and secondary efficacy outcome and its components are based on the first occurrence to participant.
Time frame: Up to 12 months, at least 6 months
Number of Participants With First Treatment-emergent Major Bleeding
The principal safety outcome was major bleeding which was defined according to the criteria of the International Society on Thrombosis and Hemostasis (ISTH) as clinically overt bleeding and associated with a fall in hemoglobin of 2 gram per deciliter (g/dL) or more, or leading to a transfusion of 2 or more units of packed red blood cells or whole blood, or occurring in a critical site, e.g. intracranial, intraspinal, intraocular, pericardial, intra articular, intramuscular with compartment syndrome, retroperitoneal, or contributing to death. Incidence of the composite of the primary and secondary efficacy outcome and its components are based on the first occurrence to participant.
Time frame: Up to 12 months, at least 6 months
Number of Participants With the Composite of the Primary Efficacy Outcome, Myocardial Infarction, Ischemic Stroke or Systemic Non-CNS Embolism
The secondary efficacy outcome is the composite of the primary efficacy outcome, myocardial infarction (MI), ischemic stroke or non-central nervous system (CNS) systemic embolism. Incidence of the composite of the primary and secondary efficacy outcome and its components are based on the first occurrence to participant.
Time frame: Up to 12 months, at least 6 months
Number of Participants With Non-major Bleeding Associated With Study Drug Interruption for > 14 Days
The secondary safety outcome was clinically relevant non-major (CRNM) bleeding, which was adjudicated by the CIAC using the ASA criteria: the bleeding was non-major and the bleeding was associated with a study medication interruption of more than 14 days.
Time frame: Up to 12 months, at least 6 months
In total 3439 participants were screened at 244 sites in 31 countries from 05-Mar-2014 (First Patient First Visit) to 15-Mar-2016 (Last Patient First Visit).
| Milestone | Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD | Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD | Acetylsalicylic (ASA) 100 mg, OD |
|---|---|---|---|
| Started | 1127 | 1107 | 1131 |
| Completed | 984 | 969 | 949 |
| Not completed | 143 | 138 | 182 |
| Withdrew: Adverse event | 51 | 47 | 46 |
| Withdrew: Death | 0 | 2 | 3 |
| Withdrew: Withdrawal by subject | 29 | 18 | 26 |
| Withdrew: Protocol violation | 3 | 5 | 3 |
| Withdrew: Lost to follow-up | 1 | 3 | 4 |
| Withdrew: Non-compliance with study medication | 21 | 19 | 23 |
| Withdrew: Physician decision | 0 | 1 | 1 |
| Withdrew: Logistical difficulties | 6 | 5 | 2 |
| Withdrew: Efficacy outcome reached | 18 | 16 | 57 |
| Withdrew: Safety outcome reached | 12 | 20 | 10 |
| Withdrew: Other | 2 | 2 | 7 |
The primary efficacy outcomes (i.e., recurrent venous thromboembolism \[VTE\] defined as composite of fatal or non-fatal symptomatic recurrent VTE, including unexplained death for which pulmonary embolism \[PE\] could not be ruled out) as confirmed by the central independent adjudication committee (CIAC) were considered up to the end of the individual intended duration of treatment. Incidence of the composite of the primary and secondary efficacy outcome and its components are based on the first occurrence to participant.
| participants | Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD | Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD | Acetylsalicylic (ASA) 100 mg, OD |
|---|---|---|---|
| Composite | 13 | 17 | 50 |
| Symptomatic recurrent Deep vein thrombosis (DVT) | 8 | 9 | 29 |
| Symptomatic recurrent PE | 5 | 6 | 19 |
| Death (PE) | 0 | 0 | 1 |
| Death (unexplained and PE cannot be ruled out) | 0 | 2 | 1 |
The principal safety outcome was major bleeding which was defined according to the criteria of the International Society on Thrombosis and Hemostasis (ISTH) as clinically overt bleeding and associated with a fall in hemoglobin of 2 gram per deciliter (g/dL) or more, or leading to a transfusion of 2 or more units of packed red blood cells or whole blood, or occurring in a critical site, e.g. intracranial, intraspinal, intraocular, pericardial, intra articular, intramuscular with compartment syndrome, retroperitoneal, or contributing to death. Incidence of the composite of the primary and secondary efficacy outcome and its components are based on the first occurrence to participant.
| participants | Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD | Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD | Acetylsalicylic (ASA) 100 mg, OD |
|---|---|---|---|
| Any major bleeding | 5 | 6 | 3 |
| Fatal bleeding | 0 | 1 | 1 |
| Non-fatal critical organ bleed | 2 | 4 | 1 |
| Non-fatal non-critical organ bleeding | 3 | 1 | 1 |
The secondary efficacy outcome is the composite of the primary efficacy outcome, myocardial infarction (MI), ischemic stroke or non-central nervous system (CNS) systemic embolism. Incidence of the composite of the primary and secondary efficacy outcome and its components are based on the first occurrence to participant.
| participants | Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD | Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD | Acetylsalicylic (ASA) 100 mg, OD |
|---|---|---|---|
| Composite | 18 | 19 | 56 |
| Ischemic stroke | 4 | 2 | 2 |
| Non-CNS systemic embolism | 1 | 0 | 1 |
| Myocardial infarction | 0 | 1 | 4 |
| Symptomatic recurrent DVT | 8 | 9 | 29 |
| Symptomatic recurrent PE | 5 | 6 | 18 |
| Death (PE) | 0 | 0 | 1 |
| Death (unexplained and PE cannot be ruled out) | 0 | 1 | 1 |
| Death (cardiovascular: myocardial infarction) | 0 | 0 | 0 |
| Death (cardiovascular: ischemic stroke) | 0 | 0 | 0 |
The secondary safety outcome was clinically relevant non-major (CRNM) bleeding, which was adjudicated by the CIAC using the ASA criteria: the bleeding was non-major and the bleeding was associated with a study medication interruption of more than 14 days.
| participants | Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD | Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD | Acetylsalicylic (ASA) 100 mg, OD |
|---|---|---|---|
| Number of Participants With Non-major Bleeding Associated With Study Drug Interruption for > 14 Days | 12 | 17 | 12 |
Collected over From after start of study medication but not more than 2 days after stop of study medication.. Non-serious events are listed at a 0.3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD | — | 78/1,127 (6.9%) | 40/1,127 (3.5%) |
| Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD | — | 82/1,107 (7.4%) | 35/1,107 (3.2%) |
| Acetylsalicylic (ASA) 100 mg, OD | — | 79/1,131 (7%) | 38/1,131 (3.4%) |
| Event | Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD | Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD | Acetylsalicylic (ASA) 100 mg, OD |
|---|---|---|---|
| PneumoniaInfections and infestations | 2/1127 | 5/1107 | 3/1131 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 3/1127 | 0/1107 | 5/1131 |
| Urinary tract infectionInfections and infestations | 2/1127 | 4/1107 | 0/1131 |
| Atrial fibrillationCardiac disorders | 1/1127 | 3/1107 | 1/1131 |
| SepsisInfections and infestations | 1/1127 | 3/1107 | 2/1131 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/1127 | 3/1107 | 3/1131 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/1127 | 1/1107 | 1/1131 |
| Suicide attemptPsychiatric disorders | 3/1127 | 0/1107 | 0/1131 |
| FallInjury, poisoning and procedural complications | 1/1127 | 0/1107 | 3/1131 |
| Femur fractureInjury, poisoning and procedural complications | 0/1127 | 0/1107 | 3/1131 |
| Event | Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD | Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD | Acetylsalicylic (ASA) 100 mg, OD |
|---|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 8/1127 | 3/1107 | 3/1131 |
| ConstipationGastrointestinal disorders | 2/1127 | 0/1107 | 7/1131 |
| Atrial fibrillationCardiac disorders | 6/1127 | 2/1107 | 3/1131 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 1/1127 | 5/1107 | 6/1131 |
| RashSkin and subcutaneous tissue disorders | 5/1127 | 3/1107 | 3/1131 |
| Abdominal pain upperGastrointestinal disorders | 2/1127 | 2/1107 | 5/1131 |
| DiarrhoeaGastrointestinal disorders | 4/1127 | 4/1107 | 1/1131 |
| VomitingGastrointestinal disorders | 0/1127 | 4/1107 | 2/1131 |
| Upper respiratory tract infectionInfections and infestations | 1/1127 | 4/1107 | 3/1131 |
| DizzinessNervous system disorders | 4/1127 | 4/1107 | 3/1131 |
| Age, Continuous(years) | Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD | Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD | Acetylsalicylic (ASA) 100 mg, OD | Total |
|---|---|---|---|---|
| Mean | 58.8 ± 14.7 | 57.9 ± 14.7 | 58.8 ± 14.7 | 58.5 ± 14.7 |
| Sex: Female, Male(Participants) | Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD | Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD | Acetylsalicylic (ASA) 100 mg, OD | Total |
|---|---|---|---|---|
| Female | 507 | 505 | 488 | 1500 |
| Male | 620 | 602 | 643 | 1865 |
| Ethnicity (NIH/OMB)(Participants) | Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD | Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD | Acetylsalicylic (ASA) 100 mg, OD | Total |
|---|---|---|---|---|
| Hispanic or Latino | 31 | 31 | 30 | 92 |
| Not Hispanic or Latino | 892 | 899 | 889 | 2680 |
| Unknown or Not Reported | 204 | 177 | 212 | 593 |
| Race (NIH/OMB)(Participants) | Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD | Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD | Acetylsalicylic (ASA) 100 mg, OD | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 2 | 4 |
| Asian | 161 | 159 | 159 | 479 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 2 | 4 |
| Black or African American | 41 | 49 | 36 | 126 |
| White | 786 | 772 | 786 | 2344 |
| More than one race | 1 | 0 | 5 | 6 |
| Unknown or Not Reported | 135 | 126 | 141 | 402 |
Showing the first 100 of 267 sites across 31 countries. Choose a country and city above to see the rest.
Ran from Mar 2014 to primary completion in Sep 2016, 30 months.
Results were first posted in Dec 2017, 1 year 2 months after primary completion.
Of 31 phase 3 interventional studies under Pulmonary Embolism, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 57. This study's 30 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rivaroxaban